arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Global Pharmaceutical and Biotechnology Conference

London |
Speakers include:
Lord Drayson PhD

Lord Drayson PhD

Sensyne Health

Jackie Hunter

Jackie Hunter

Benevolent AI

Harpal Kumar

Harpal Kumar

Johnson & Johnson


Disruption and transformation will continue to be the focus of life science leaders in 2019 and beyond. 

Pricing pressures in the US and a growing number of markets globally has already set in motion a search for new and innovative payment models, while the rise of ultra-expensive, potentially curative gene and cell therapies has brought to the fore a heated discussion about the sustainability of industry’s underlying economic and funding model.

With a host of ‘new entrants’ in the shape of big tech and nimble, consumer-centric start-ups nibbling at pharma’s heals in the emerging prevention and wellness space, meanwhile, pharma faces competition on an increasing number of fronts. Success in the new data and patient-centric world which is emerging will increasingly depend on the forging relationships with patients sustained on trust, and building new business models for the future.

fallback Add to my Calendar 11/11/2019 13:15:0011/12/2019 17:30:00trueFT Global Pharmaceutical and Biotechnology ConferenceDisruption and transformation will continue to be the focus of life science leaders in 2019 and beyond. Pricing pressures in the US and a growing number of markets globally has already set in motion a search for new and innovative payment models, while the rise of ultra-expensive, potentially curative gene and cell therapies has brought to the fore a heated discussion about the sustainability of industry’s underlying economic and funding model.With a host of ‘new entrants’ in the shape of big tech and nimble, consumer-centric start-ups nibbling at pharma’s heals in the emerging prevention and wellness space, meanwhile, pharma faces competition on an increasing number of fronts. Success in the new data and patient-centric world which is emerging will increasingly depend on the forging relationships with patients sustained on trust, and building new business models for the future.FT-Global-Pharmaceutical-and-Biotechnology-Conference4da62f606ea64163d2a341ae0a173256MM/DD/YYYY

2018 Photos

View photos from the 2018 Summit here.

FT Pharma Bio 2018-8920


Speakers (6)

Lord Drayson PhD

Lord Drayson PhD

Chief Executive Officer
Sensyne Health
Jackie Hunter

Jackie Hunter

Chief Executive, Clinical Programmes and Strategic Relationships
Benevolent AI
Harpal Kumar

Harpal Kumar

Head of Johnson & Johnson Innovation, EMEA
Johnson & Johnson
Pierre Meulien

Pierre Meulien

Executive Director
Innovative Medicines Initiative (IMI)
Heather  Bresch

Heather Bresch

Chief Executive Officer

Heather Bresch is the Chief Executive Officer of Mylan. She also serves on the company’s board of directors. As CEO, she is responsible for a workforce of more than 35,000, a powerful global research and development platform, a manufacturing footprint comprising more than 4O facilities and a portfolio of more than 7,500 generic and branded pharmaceuticals sold in more than 165 countries and territories.  Throughout her more than 25-year career with Mylan, Ms Bresch, who started with the company as a data-entry clerk, has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, she served as Mylan’s President, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan’s Chief Operating Officer and Chief Integration Officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled the size of the company. Ms Bresch emphasizes a collaborative company culture focused on leading, learning, teaching and performing to inspire innovation and help set new standards in healthcare.

Kåre  Schultz

Kåre Schultz

President and CEO

Kåre Schultz became Teva's President and CEO in November 2017. Mr Schultz is a seasoned veteran in the healthcare industry who has distinguished himself through his experience leading financial and restructuring initiatives at global companies. From 2015 to, 2017 he has served as the President and Chief Executive Officer of H. Lundbeck A/S, which he joined as the company was facing the loss of critical patents. Mr Schultz conducted a top to bottom evaluation of the business and implemented a robust turnaround strategy that involved cutting operating costs while targeting new product launches. Prior to joining Lundbeck, Mr Schultz worked for nearly three decades at Novo Nordisk, where he served in a number of leadership roles, including Chief Operating Officer, Vice President in Product Supply and Director of Product Planning and Customer Services in the Diabetes Care Division. At Novo Nordisk, Mr Schultz played a major role in modernizing the company’s large scale biologic production and leading the company’s expansion into the US and Chinese markets. In addition to his time at Novo Nordisk, Mr Schultz has held positions at McKinsey and Anderson Consulting. In these roles, he developed a unique global perspective on the healthcare and pharmaceutical industries, expanded his deep financial acumen, demonstrated a commitment to strong compliance principles and enforcement and oversaw business operations and teams across Europe and North America and the Middle East. Mr Schultz serves as a member of the Board of Directors of LEGO A/S. He also served as the Chairman of the Board of Directors of Royal Unibrew A/S, and as a member of the Board of Directors of Bitten og Mads Clausens Fond, the holding vehicle for Danfoss A/S. He holds a Master’s degree in Economics from the University of Copenhagen.



Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Hannah Kuchler

Hannah Kuchler

Financial Times

Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. She is based in San Francisco.  For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York.  Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.

Advisory Board (11)

Virginia Acha

Virginia Acha

Executive Director-Global Regulatory Policy, R&D Innovation Centre

Virginia (Ginny) Acha has worked in industry and academia throughout her career, combining interests in science policy research and innovation performance within and across organisations.  She recently joined MSD to lead regulatory policy efforts for innovation that will lead to better treatment for patients in Europe, the Middle East, Africa and Asia.  In particular, she is supporting work on real world evidence and integrated evidence generation. Before joining MSD, Dr Acha was the senior spokesman for the industry in the UK for research, medical and innovation policy.  She was responsible for ABPI’s work on Brexit for the life sciences sector.  Previously, Dr Acha worked for Amgen in global regulatory policy and for Pfizer working on policy development in science and innovation in healthcare. 

Lisa  Anson

Lisa Anson

Redx Pharma

Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed in June 2018. She held the post of President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Ms Anson held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams. She joined Zeneca Pharmaceuticals (USA) in 1998 as a business development manager. Prior to this she worked for Salick Health Care (now Aptium), a California based cancer disease management company. Her first position upon graduating from university was with KPMG in London as a management consultant

Ms Anson is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government.

Ms Anson holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. 

Alexandra Bause

Alexandra Bause

Founding Partner
Apollo Ventures

Alexandra is a founding member and partner at Apollo Ventures, a biotech company builder and investment fund focused on developing interventions to improve human health and longevity. At Apollo, Alexandra is leading the venture creation programs that aim to found new biotech startups targeting the aging process at a molecular level. She is also managing the pipeline and diligence process for external investment opportunities, predominantly focusing on preclinical-stage biotech companies. 

Before joining Apollo Ventures, Alexandra worked with The Boston Consulting Group where she specialized in biopharma strategy, market assessment and asset diligence. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. She is also a trained pharmacist with expertise in pharmaceutics and pharmacology.

Jeanne Bolger

Jeanne Bolger

Vice President, Venture Investments
Johnson & Johnson Development Corporation (JJDC)
Richard  Mason

Richard Mason

The Foundation Institute for 21st Century Medicine (C21Med)

Richard Mason, MD, is Co-Founder of The Foundation Institute for 21st Century Medicine (‘C21Med’), an initiative of venture capital firm Medicxi

Dr. Mason served as Head of Johnson & Johnson’s London Innovation Centre from October 2015 to April 2018, where he was responsible for Johnson & Johnson Innovation within the EMEA region. In this role, Dr. Mason led a team of transaction and scientific innovation experts to identify and develop a diverse portfolio of early-stage partnerships and investments across all three sectors of J&J.
Prior to joining J&J, Dr Mason was CEO of a venture-backed biotechnology startup, XO1 Ltd. until the company was acquired by Janssen Pharmaceuticals (a subsidiary of J&J) in March 2015. Prior to that, he was Head of Strategy and Business Development and member of Executive Leadership Team at specialty pharmaceutical and medical device company BTG Plc (LON: BTG), where he led its transformation into a leading interventional medicine company through multiple acquisitions including Ekos Corporation, Biocompatibles Plc, and MDS Nordion’s Therasphere business. Dr.Mason also served as an Executive-in-Residence for Advent Venture Partners where he served as a turnaround CEO for several portfolio companies. Prior to that he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT) and member of the CAT Executive Leadership Team.
Dr. Mason trained in Medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from University College, London and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management.

Mark Samuels

Mark Samuels

Chief Business & Strategy Officer
Medicines Discovery Catapult

Mark Samuels is Chief Business & Strategy Officer at the Medicines Discovery Catapult. In this role, he is responsible for business development, strategy, communications and research consortia. Previously, Mr Samuels founded the national Office for Clinical Research Infrastructure and was a founder member of the NIHR Strategy Board. With £1.1bn annual budget, the NIHR is responsible for NHS research across England. Mr Samuels also worked with Number 10 on David Cameron’s strategy for life sciences. At HIHR he established the organisation’s Translational Research Collaborations and chaired the creation of the UK’s Stem Cell Transplant Clinical Trials Partnership. Before NIHR, Mr Samuels was an executive at Roche Diagnostics. Representing the UK diagnostics industry, he co-chaired with Sir Andrew Dillon creation of the programme for NICE to evaluate diagnostics and medical devices. Educated at QMUL and Saïd Business School, Mr Samuels holds a Policy Fellowship at Cambridge University.

Mike Standing

Mike Standing

EMEA Life Sciences and Healthcare Lead

Mike Standing is the Life Sciences and Healthcare industry leader for Deloitte for EMEA. Mr Standing has consulted to leading pharmaceutical and healthcare organisations in Europe, US and China for over 20 years, focusing on commercial strategy, operations and R&D productivity. In addition, he is currently leading major programmes to understand how real world evidence can transform health outcomes and productivity. He also advises governments on building healthcare clusters and is a member of the UK's Global Medical Excellence Cluster (GMEC) Advisory Board. Prior to joining Deloitte, Mr Standing was Co-Head of Life Sciences for the Monitor Group and Global Head of Capgemini's Life Sciences business. He is a graduate of Durham and Cambridge Universities and is based in London.

Andy Garrett

Andy Garrett

Executive Vice President, Scientific Operations
Sarah Maxfield

Sarah Maxfield

VP of Sales
Europe & Asia at FUJIFILM Diosynth Biotechnologies
Faraz Kermani

Faraz Kermani

Sr. Manager European Commercial Communications, External Communications
CSL Behring
Chris Surridge

Chris Surridge

Director of Strategy and Commercial Excellence

Agenda - 11th Nov

  • 1:15pm
    Opening Remarks from the Chair
  • 1:20pm
    Keynote Address/Interview
  • 1:35pm
    Panel: Who Owns the Patient? The Disruption to Come

    As healthcare increasingly moves from treatment to prevention, pharma companies encounter a growing number of ‘new entrants’ with whom they will compete for patients’ loyalty and data. Big tech companies, as well as, innovative new start-ups are at the centre of the shift, using complex digital tools and algorithms to help patients stay healthy and manage their conditions. Retailers, insurers and consumer brands are also entering the fray, while pharma companies are making tentative first steps with their own versions of disease management technologies and services. Gaining access to patient data is key. At a time when concerns regarding data quality, integrity and privacy of patient data are paramount, building robust evidence to back health claims, as well as relationships with patients based on trust will be central to success.

    • What role will pharma play in this population health space?
    • Will patients trust consumer and tech brands over pharma?
    • How robust are these health algorithms, and how will digital apps and therapies stack up against growing demand for evidence and validation? Or are lifestyle interventions a ’new kind of medicine’ which can be held to different standards of evidence?
    • What will it mean for pharma when more health data will reside outside the traditional healthcare system than within it?
  • 2:25pm
    Keynote Address/ Interview/Presentation
  • 2:40pm
    Networking Coffee Break
  • 3:00pm
    Turning the Big Pharma Ship - Transformation and Talent Strategies

    Pharma companies are likely to undergo a significant shake-up as they position themselves for a rapidly changing healthcare landscape. Success, to a large extent, will depend on their ability to attract, develop and retain high-performance talent from across a wide range of industries, develop new operational and organisational models, and break down the silos which are inhibiting innovation.

    • How are pharma companies managing the transformation in terms of governance, operational and organisational change?
    • How can pharma companies foster innovation, entrepreneurial spirit and the calling to ‘innovative like a start-up’?
    • What are the leading-edge strategies for recruitment, development and retention success?
    • How do you create a value proposition for pharma that will attract millennials and much-needed data scientists? How do you prevent new talent ‘going native’?
    • How are global workforce trends impacting pharma (robotics, millennials, remote working, etc) and what will the pharma company of the future look like?
    • How will the transition of leadership talent from pharma to biotech impact the future pipeline of the industry?
  • 3:50pm
    Panel: Chief Digital Officer Forum

    Chief Digital Officers (CDOs), often appointed from other industries, to include consumer, provide a unique perspective on the transformation underway in the industry. What have been their experiences to date, and what have been the obstacles they have experienced along the way? How are they building digital pharma companies? How are they dealing with the transition from consumer, data and other industries to the world of pharma, and how has their role evolved? What are their observations regarding the industry, the transformation that is needed, and the way ahead?

  • 4:40pm
    Keynote Address/ Interview/Presentation
  • 4:55pm
    End of Day One

Agenda - 12th Nov

  • 9:05am
    Keynote Address/ Interview/Presentation
  • 9:20am
    Panel: Resolving Pharma’s Pricing Conundrum: A New Prescription

    From the US President’s Pricing Blueprint, to moves towards EU wide drug procurement, pressure on the industry’s pricing model is growing. The advent of ultra-expensive and potentially curative gene and cell therapies, meanwhile, is also adding to the momentum for change. The status quo is no longer working. If the industry is to remain in driving seat, it is going to have to accept that new ways of funding this industry and innovative pricing models will be necessary. This will have a potentially transformative impact on the economic model of the industry and the way it funds R&D. What would a sustainable innovation funding model look like?

    • Are subscription / Netflix-type pricing models the future?
    • Will outcome-based pricing become the norm? What’s the devil in the detail? How are pioneers dealing with complexity?
    • How do you price and finance a cure? What could be the role for reinsurance and other innovative pricing models?
    • How do you price digital therapies? Offering the potential for ‘cures’, should they be priced ‘just like a drug’?
    • Given the inflationary impact of pharma’s current high-risk, high reward funding model, are there alternative and better ways of funding drug innovation? Is there a need for governments to be involved, particularly in ensuring unmet needs are financed?
    • Does recent experience with Anti-Microbial Resistance (AMR) show the way ahead in terms of innovative funding which could be applied to many other diseases? What is the evidence that government involvement and risk-taking yields faster drugs at lower prices?
    • What could be the role of prize funds, venture philanthropy and patient financing?
  • 10:10am
    Networking Coffee Break
  • 10:30am
    Keynote Address/ Interview/Presentation
  • 10:50am
    Panel: Intellectual Property: Is the Current System Still Fit for Purpose?

    In the distant past, society decided to strike a Grand Bargain of IP, providing innovators a monopoly for a set number of years to recover costs and ensure a return, thus striking a balance between incentives and societal benefit. Some allege, though, that pharma has found ways to unfairly manipulate the IP system, keeping costs sky-high for decades. And pressure is steadily mounting for change. Can industry players compromise before the heavy hand of government steps in?

  • 11:30am
    Rewarding Innovation: What is the Regulation we Need?

    Regulation matters. The global financial crisis illustrates what can happen when regulation fails to keep track on changes in the industry. For life sciences, this means keeping up to date with advances in technologies including digital and AI, as well as advances in cutting-edge science to include cell and gene therapies. And it also means knowing what society wants from regulation of the industry - finding the bright balance between safety and ‘right to try’, for instance. With a change of guard underway at the FDA. the possibility of EU health directorate re-opening the regulatory rule book and a review of regulatory science underway, it is opportune to ask what kind of regulation we want to ensure we get the innovation we need.

  • 12:10pm
    Keynote Interview/Presentation
  • 12:25pm
  • 1:35pm
    Panel: Digital R&D: AI-The Reckoning?

    The burgeoning field of AI is attracting increasing amounts if investment form pharma companies who are putting their faith in the technologies ability to drug the next big leaps in drug development. Opinions differ, however, on the extent that AI will bring down costs in R&D or find cures, with no drugs yet discovered or commercialised with AI. The complexities of implementation, the issues of data collection, quality and need for scale, meanwhile, are often underplayed amidst the hype. Where will AI add value to pharma R&D, and where will it not? Are current algorithms focusing on the right things? How are standalone AI drug companies doing things differently, and when might we see the first AI developed drug?

  • 2:25pm
    Keynote Interview/Presentation
  • 2:40pm
    Panel: The Global Competition for Investment: How Will the Clusters Fare?

    How will Brexit impact the competitive position of the UK as a leading global science hub?

    • Is the UK’s Industrial Strategy a sufficient response, or will the likely impact of Brexit outweigh the potential benefits? What does the UK need to do to stay ahead?
    • Will the US maintain its status as the world leader in R&D expenditure for pharma, in patents and as a centre if pharma innovation? How will the expected lowering of drug prices and NIH support impact its position?
    • Will China steal a lead by virtue of largely laissez-faire approach to regulation and growing prowess in AI, genome sequencing and advanced cell and gene therapies?
    • How are investors viewing the relative competitiveness of the clusters in view of these transitions underway?
    • The new cluster success stories: how are they attracting investment?
  • 3:30pm
    Into the Den: The Next Big Thing? Innovation on the Frontiers or Science, Medicine and Technology

    Where is science and technology taking the future of medicine? What are the emerging areas and as yet little know areas of therapeutic focus (targets modalities, technologies) which could have a big impact on patient outcomes and become the potential growth drivers of the future? What is hype and what is real? Is the industry doing enough to leverage experience and expertise of diverse industries and domains including engineering, mathematics, physics, for instance, and what are the possibilities? This session will feature a number of quick-fire presentations of potentially game-changing science and technologies, followed by a panel discussion of leading VCs and an audience vote on likely winners.

  • 4:20pm
    In Conclusion: Can Pharma do Better at Telling its Story?

    For an industry whose business is saving lives and curing diseases, pharma has an unenviable reputation, even when compared to other players in the healthcare system. Meanwhile, the tech companies with which pharma must increasing compete or collaborate, enjoy positive perceptions as ‘disruptors’ and a ‘constructive force for good’ for consumers. With pharma under siege on a multitude of fronts, does the industry need to get better at communicating its value story? How did the industry get here, and how can it rebuild trust? Can a focus on closer partnerships with HCP/health service based on improving outcomes, for instance, help win trust and nurture support? How can the industry build trust to be seen as a partner of choice with others in the ever-extending industry value chain and with patients?

  • 5:00pm
    End of Conference


  • Debate the role of super clusters and industrial strategy in creating a ‘big bang’ in life sciences
  • Discover how China’s novel approaches to R&D, data and digital health are creating innovate treatment and service models
  • Discuss what it takes for pharma to win in population health management and the business of prevention
  • Learn how innovative gene-based therapies are transforming the industry paradigm from treatment to cure and the pricing strategies to manage it.
  • Envision the future of diagnostics and personalised medicine
  • Hear from leading fund managers, corporate venturers, and other investors on where they are placing bets in pharma
  • Be part of the discussion on value and evidence and the challenge of managing the increasing volume and complexity of big data


FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.

The FT Global Pharmaceutical and Biotechnology Conference will be attended by:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostic and medical device
  • CROs
  • Healthcare providers and insurers
  • Government healthcare departments, HTA’s and drug regulators
  • IT, big data and analytics providers
  • Health economists
  • Healthcare investment bankers, private equity
  • Patient representatives and NGOs


  • Gain access to 350 Senior Executives from the International Pharmaceutical Industry, who will be attending the event;
  • Brand alignment with the FT and its unrivalled credibility;
  • Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
  • Benefit from sustained international visibility through our advertising and marketing campaigns

Joe Hames

Commercial Manager, Global Industries

T: +44 (0)207 873 4551

M: +44 (0)791 329 2038






Super Early Bird Rate - Extended until 19 April


Early Bird Rate - from 20 April - 17 May


Standard Ticket Price - from 18 May onwards



Presented By (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

With the support of (1)

About Life Sciences and Health Care at Deloitte

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

Global Clinical Research Partner (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,650 employees. For further information please visit  Follow @iconplc on Twitter.

Lead Sponsor (2)

Association Partner (1)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 40 leading pharmaceutical companies, EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients. 


Royal Lancaster
Lancaster Terrace
London W2 2TY

United Kingdom

Tel: +44 207 551 6000



Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times